AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35279143
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg single-dose primaquine
Trial: 35279152
Drug: Carboplatin/paclitaxel (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/paclitaxel (standard of care chemotherapy)
Trial: 35279152
Drug: MYC/MAX dimerization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYC/MAX dimerization inhibitor (10058-F4)
Trial: 35279271
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pembrolizumab intravenously every 3 weeks for 6 months (eight cycles)
Trial: 35279811
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m²) administered as four weekly intravenous infusions
Trial: 35280363
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg) combined with paclitaxel (135 mg) and cisplatin as neoadjuvant therapy.
Trial: 35280363
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (nCRT) as the standard treatment under NCCN guidelines.
Trial: 35280802
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) regimens
Trial: 35280802
Drug: SOXA (apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOXA (apatinib in combination with S-1 and oxaliplatin) cohort
Trial: 35281856
Drug: Vismodegib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (150 mg orally once a day for a 21-day cycle)
Trial: 35282037
Drug: Apatinib mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate (500 mg qd) plus pemetrexed (500 mg/m2)
Trial: 35282136
Drug: Hetrombopag (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag (5 mg orally once daily for up to 6 weeks)
Trial: 35283104
Drug: benralizumab (30-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benralizumab (30-mg subcutaneous dose)
Trial: 35283460
Drug: Alternative dosing
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative dosing forms of hydrocortisone
Trial: 35283460
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone receptor antagonists
Trial: 35283460
Drug: Androgen biosynthesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen biosynthesis inhibitors
Trial: 35283460
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy vector
Trial: 35283693
Drug: Prostate-specific membrane
RxNorm normalized name: Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT)
Trial: 35285405
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy (HF-RT) with nodal simultaneous integrated boost (nSIB) at a dose of 2.67 Gy x 15 fractions
Trial: 38320431
Drug: Dose-limiting toxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-limiting toxicity (DLT)
Trial: 35285484
Drug: Panitumumab, chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab, chemotherapy, and external beam radiation therapy
Trial: 35285786
Drug: Fostemsavir 600
RxNorm normalized name: fostemsavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 600 mg BID for 4 days
Trial: 35285786
Drug: Maraviroc 300
RxNorm normalized name: maraviroc 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 300 mg BID for 5 days
Trial: 35285786
Drug: Fostemsavir 600
RxNorm normalized name: fostemsavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 600 mg BID with Maraviroc 300 mg BID for 7 days
Trial: 35286612
Drug: Topical/traditional systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical/traditional systemic agents
Trial: 35287469
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg once daily administered orally
Trial: 35287613
Drug: nab-paclitaxel 260
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 260 mg/m²
Trial: 35287672
Drug: Sandoz biosimilar
RxNorm normalized name: CLOZAPINE (SANDOZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandoz biosimilar filgrastim (twice-daily)
Trial: 35287719
Drug: Higher adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher adrenaline dose during cardiopulmonary resuscitation
Trial: 35287719
Drug: Previous proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous proton pump inhibitor use
Trial: 37118832
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow mononuclear cell (BMMNC) infusion
Trial: 35287967
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal
Trial: 35287972
Drug: PCSK9 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors (overall)
Trial: 35288468
Drug: Itacitinib (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (100-400 mg once a day) plus epacadostat (50-300 mg two times per day)
Trial: 35288468
Drug: Itacitinib (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (100-400 mg once a day) plus parsaclisib (0.3-10 mg once a day)
Trial: 35288511
Drug: AI-graded daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI-graded daily average BSS scores
Trial: 35289267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of maximum standardised uptake value and peak enhancement
Trial: 35289310
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies
Trial: 35290461
Drug: School-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based screening and treatment with artemether-lumefantrine
Trial: 35291289
Drug: 100-μg mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-μg mRNA-1273 booster dose
Trial: 35291289
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (second dose of mRNA-1273)
Trial: 35291977
Drug: Lapatinib 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,250 mg orally once per day continuously plus capecitabine (1,000 mg/m2)
Trial: 35292609
Drug: Dose adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose adjustment based on TDM measurements
Trial: 35292724
Drug: Avelumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (10 mg/kg every 2 weeks)
Trial: 35293984
Drug: Pegloticase (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase (8 mg biweekly infusions) + oral MTX (15 mg/week) co-therapy
Trial: 35294522
Drug: Ribociclib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib + binimetinib (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off)
Trial: 35294527
Drug: Systemic treatments
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatments (44 patients, 8.5%)
Trial: 35294811
Drug: Valoctocogene roxaparvovec
RxNorm normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy, single infusion of 6×10^13 vg/kg
Trial: 35294811
Drug: Valoctocogene roxaparvovec
RxNorm normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy
Trial: 35295414
Drug: Neuromodulation (intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulation (intrathecal therapy, spinal cord stimulation, or dorsal root ganglion stimulation)
Trial: 35295414
Drug: Pain medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medications
Trial: 35295414
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (medications)
Trial: 35295488
Drug: Probiotic VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic VSL#3 Treatment
Trial: 35295665
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of intravenous amoxicillin (HDIVA)
Trial: 36043180
Drug: Regdanvimab 40
RxNorm normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Regdanvimab 40 mg/kg
Trial: 35295819
Drug: Regdanvimab 80
RxNorm normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Regdanvimab 80 mg/kg
Trial: 35296254
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs (PDs)
Trial: 35296254
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications
Trial: 35296254
Drug: Antipsychotics, antidepressants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics, antidepressants, and sedative substances
Trial: 35296254
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication
Trial: 35296254
Drug: Antipsychotics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics and sedative substances
Trial: 35296895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10-minute Apgar score with other risk variables
Trial: 35296961
Drug: Ophthalmological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmological treatment
Trial: 35297025
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg subcutaneous injection every 2 weeks
Trial: 35297944
Drug: Any adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any adjuvant chemotherapy
Trial: 35297944
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 4 cycles of adjuvant platinum-based chemotherapy
Trial: 35297944
Drug: Any cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any cisplatin-based adjuvant chemotherapy
Trial: 35298296
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks (Cohort 1)
Trial: 35298296
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg once daily plus nivolumab 480 mg once every 4 weeks (Cohort 1)
Trial: 35298698
Drug: Cetrelimab 80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W (Phase 1)
Trial: 35298698
Drug: Cetrelimab 240
RxNorm normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrelimab 240 mg Q2W (Phase 2)
Trial: 35299035
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (third or fourth-line treatment)
Trial: 35299273
Drug: Near-infrared (NIR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near-infrared (NIR) contrast agent labeled with IRDye800 administered topically to patients with Barrett's esophagus.
Trial: 35299970
Drug: Abnormal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormal glucose metabolism parameters (including DM, hyperinsulinemia, and insulin resistance)
Trial: 35299970
Drug: Postprandial 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial 2 h blood glucose ≥11.1mmol/L and HbA1c ≥6.5%
Trial: 35301822
Drug: Brolucizumab 6
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab 6 mg intravitreal injection
Trial: 35302585
Drug: ARRY-382 200-400
RxNorm normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARRY-382 200-400 mg QD plus pembrolizumab 2 mg/kg IV Q3W (Phase 1b)
Trial: 35302585
Drug: ARRY-382 300
RxNorm normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARRY-382 300 mg QD plus pembrolizumab 200 mg IV Q3W (Phase 2)
Trial: 35303007
Drug: CAR-T IS
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T IS quality measurement using ML-based method
Trial: 35303007
Drug: ML-based automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-based automated algorithm for quantifying CAR-T IS data
Trial: 35303070
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg orally twice daily
Trial: 35303201
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL) score (0=disability, 6=no disability)
Trial: 35304622
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg IV on day 1), Apatinib (500 mg oral once daily), S-1 (specific dose oral for first 14 days)
Trial: 35304622
Drug: Camrelizumab, Apatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab, Apatinib, and S-1 combination therapy
Trial: 35304684
Drug: Adalimumab biosimilar
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab biosimilar PF-06410293 (ADL-PF) 40 mg via prefilled syringe (PFS) and single-use PFP device
Trial: 35305102
Drug: Toripalimab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (240 mg, day 1) plus paclitaxel (135 mg/m2, day 1) and carboplatin (AUC 5 mg/mL per min, day 1) for 2 cycles
Trial: 35305400
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg intravenously every 3 weeks until loss of clinical benefit or unacceptable toxicity
Trial: 35305556
Drug: Non-nephrotoxic antibiotic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nephrotoxic antibiotic
Trial: 35305740
Drug: Ad26.COV2.S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S vaccine (Johnson & Johnson), single dose of 5×10^10 viral particles
Trial: 35306029
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (non-stent)
Trial: 35306553
Drug: Mesalazine ≥4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine ≥4 g/day
Trial: 35306553
Drug: Mesalazine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine treatment duration >6 months
Trial: 35306553
Drug: Mesalazine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine treatment duration 3-6 months
Trial: 35306594
Drug: Sinovac-CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovac-CoronaVac vaccine (two doses 28 days apart, D0/D28)
Trial: 35307611
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 1)
Trial: 35307611
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 2)
Trial: 35307611
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles
Trial: 35307972
Drug: Avelumab, axitinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, axitinib, and palbociclib (DL1: avelumab 10 mg/kg IV q2weeks, axitinib 3 mg po bid, palbociclib 75 mg po daily for 7 days off/21 days on)
Trial: 35307972
Drug: Avelumab, axitinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, axitinib, and palbociclib combination
Trial: 35308034
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of convalescent plasma (Low-volume)
Trial: 35308034
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL of convalescent plasma (High-volume)
Trial: 35308099
Drug: N8-GP (turoctocog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N8-GP (turoctocog alfa pegol) prophylaxis administered intravenously for up to 104 weeks, every 7 days, twice weekly, or three times weekly.
Trial: 35308376
Drug: 3HP treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3HP treatment (once-weekly rifapentine plus isoniazid for 3 months)
Trial: 35308535
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 40 mg intravenous dexamethasone
Trial: 35309087
Drug: Amcenestrant 200
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant 200 mg plus palbociclib 125 mg
Trial: 35309087
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg plus palbociclib 125 mg
Trial: 35310961
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy (CN) after starting systemic immune checkpoint-based combination therapy
Trial: 35310961
Drug: Continued systemic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued systemic therapy (control group)
Trial: 35313819
Drug: Wearable activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable activity tracker (Fitbit InspireHR) used for 12 weeks with personalized activity goals and weekly feedback
Trial: 35313957
Drug: Eye Tracking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Tracking (ET) tasks including Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks
Trial: 35314693
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg, 5-days-on/2-days-off, plus letrozole or fulvestrant
Trial: 35315601
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 3 years in idiopathic GHD patients
Trial: 35315601
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 3 years in organic GHD patients
Trial: 35315601
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 3 years in both idiopathic and organic GHD patients
Trial: 35315783
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment protocol (20 treatments over 4 weeks) with an intensity of 120% of resting motor threshold, frequency of 10 Hz, 10 trains of 60 pulses per train (total of 600 pulses), intertrain interval of 45 seconds.
Trial: 35315783
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment.
Trial: 35316227
Drug: Various pharmacological
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pharmacological interventions including antivirals, antimalarials, corticosteroids, NSAIDs, and antipyretics
Trial: 35316227
Drug: COVID-19 vaccines
RxNorm normalized name: Covid-19 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccines (Pfizer/BioNTech and mRNA-1273 Moderna)
Trial: 35316328
Drug: Nivolumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab alone (240 mg every 2 weeks for up to 6 cycles)
Trial: 35316328
Drug: Nivolumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab alone or in combination with NICE